Iptakalim as a human nicotinic acetylcholine receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 2, 2006, Pages 914-925

  Hu, Jun ^a,b   Lindenberger, Kari ^a   Hu, Gang ^b   Wang, Hai ^c   Lukas, Ronald J ^a   Wu, Jie ^a,b,c  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIBATIDINE; IPTAKALIM; POTASSIUM CHANNEL; RECEPTOR BLOCKING AGENT; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; CELL LINE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; PATCH CLAMP; PRIORITY JOURNAL; STEADY STATE; WHOLE CELL;

BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; CELL LINE; CLONING, MOLECULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; ION CHANNEL GATING; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PATCH-CLAMP TECHNIQUES; PROPYLAMINES; PYRIDINES; RECEPTORS, NICOTINIC; TIME FACTORS;

EID: 31144441305     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.094987     Document Type: Article

References (36)

1. Ayajiki K, Okamura T, Fujioka H, Nakayama K, Tsuji K, and Toda N (1998) Functional studies on blockade by neosurugatoxin of nicotinic receptors in nitroxidergic and sensory nerve terminals and intramural ganglionic cells. Jpn J Pharmacol 78:217-223.
2. A receptor endocytosis that contributes to the induction and maintenance of seizures in the hippocampal culture model of acquired epilepsy. J Pharmacol Exp Ther 310:871-880.
3. Burghaus L, Schütz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, Lindstrom J, and Schröder H (2000) Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 76:385-388.
4. Cordero-Erausquin M, Marubio LM, Klink R, and Changeux J-P (2000) Nicotinic receptor function: perspectives from knockout mice. Trends Pharmacol Sci 21:211-217.
5. Eaton JB, Peng J-H, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo Y-P, Steinlein O, and Lukas RJ (2003) Characterization of human α4β2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol 64:1283-1294.
6. Fenster CP, Rains MF, Noerager B, Quick MW, and Lester RA (1997) Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J Neurosci 17:5747-5759.
7. Gentry CL and Lukas RJ (2002) Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr Drug Targets CNS Neurol Disord 1:359-385.
8. Gopalakrishnan M, Monteggia LM, Anderson DJ, Molinari EJ, Iattoni-Kaplan M, Donnelly-Roberts D, Arneric SP, and Sullivan JP (1996) Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine α4β2 receptor. J Pharmacol Exp Ther 276:289-297.
9. Jonnala RR and Buccafusco JJ (2001) Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J Neurosci Res 66:565-572.
10. Levin ED, Mead T, Rezvani AH, Rose JE, Gallivan C, and Gross R (2000) The nicotinic antagonist mecamylamine preferentially inhibits cocaine vs. food selfadministration in rats. Physiol Behav 71:565-570.
11. Liu Y, He HR, Ding JH, Gu B, Wang H, and Hu G (2003) Iptkalim inhibits cocaine challenge-induced enhancement of dopamine levels in nucleus accumbens and striatum of rats by up-regulating Kir6.1 and Kir6.2 mRNA expression. Acta Pharmacol Sin 24:527-533.
12. Lopez-Hernandez GY, Sanchez-Padilla J, Ortiz-Acevedo A, Lizardi-Ortiz J, Salas-Vincenty J, Rojas LV, and Lasalde-Dominicci JA (2004) Nicotine-induced upregulation and desensitization of α4β2 neuronal nicotinic receptors depend on subunit ratio. J Biol Chem 279:38007-38015.
13. Lukas RJ, Changeux J-P, Le Novère N, Albuquerque EX, Balfour DJK, Berg DK, Bertrand D, Chiappinelli VA, Clarke PBS, Collins AC, et al. (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51:397-401.
14. Lukas RJ, Norman SA, and Lucero L (1993) Characterization of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line. Mol Cell Neurosci 4:1-12.
15. Luscher C, Xia H, Beattie EC, Carroll RC, von Zastrow M, Malenka RC, and Nicoll RA (1999) Role of AMPA receptor cycling in synaptic transmission and plasticity. Neuron 24:649-658.
16. Marubio LM, Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM, McIntosh JM, Rossi F, Champtiaux N, Zoli M, et al. (2003) Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 17:1329-1337.
17. Naguib M and Magboul MM (1998) Adverse effects of neuromuscular blockers and their antagonists. Middle East J Anesthesiol 14:341-373.
18. Nakamura S, Takahashi T, Yamashita H, and Kawakami H (2001) Nicotinic acetylcholine receptors and neurodegenerative disease. Alcohol 24:79-81.
19. O'Neill MJ, Murray TK, Lakics V, Visanji NP, and Duty S (2002) The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Targets CNS Neurol Disord 1:399-411.
20. Peng J-H, Lucero L, Fryer J, Herl J, Leonard SS, and Lukas RJ (1999) Inducible, heterologous expression of human 7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line. Brain Res 825:172-179.
21. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K, and Changeux JP (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature (Lond) 391:173-177.
22. Puchacz E, Buisson B, Bertrand D, and Lukas RJ (1994) Functional expression of nicotinic acetylcholine receptors containing rat 7 subunits in human neuroblastoma cells. FEBS Lett 354:155-159.
23. Quik M (2004) Smoking, nicotine and Parkinson's disease. Trends Neurosci 27:561-568.
24. Shytle RD, Penny E, Silver AA, Goldman J, and Sanberg PR (2002) Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens 16:453-457.
25. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, and Lester HA (2004) Nicotine activation of alpha4* receptors: sufficient for reward, tolerance and sensitization. Science (Wash DC) 306:1029-1032.
26. Wang H (1998) ATP-sensitive potassium channel as a new target for development of antihypertensive drugs. Acta Pharmacol Sin 19:257-267.
27. Wang H (2003) Pharmacological characteristics of the novel antihypertensive drug, iptakalim hydrochloride and its molecular mechanisms. Drug Dev Res 58:65-68.
28. Wang H, Zhang YL, Tang XC, Feng HS, and Hu G (2004) Targeting ischemic stroke with a novel opener of ATP-sensitive potassium channels in the brain. Mol Pharmacol 66:1160-1168.
29. Wang S, Hu LF, Yang Y, Ding JH, and Hu G (2005) Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease? Neuropharmacology 48:984-992.
30. Wu J, George AA, Schroeder KM, Xu L, Marxer-Miller S, Lucero L, and Lukas RJ (2004a) Electrophysiological, pharmacological and molecular evidence for α7-nicotinic acetylcholine receptors in rat midbrain dopamine neurons. J Pharmacol Exp Ther 311:80-91.
31. Wu J, Kuo YP, George AA, Xu L, Hu J, and Lukas RJ (2004b) βAmyloid directly inhibits human α4β2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J Biol Chem 279:37842-37851.
32. Yang Y, Liu X, Ding JH, Sun J, Long Y, Wang F, Yao HH, and Hu G (2004) Effects of iptakalim on rotenone-induced cytotoxicity and dopamine release from PC12 cells. Neurosci Lett 366:53-57.
33. Yang Y, Liu X, Long Y, Wang F, Ding JH, Liu SY, Sun YH, Yao HH, Wang H, Wu J, and Hu G (2005) Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenone-induced motor and neurochemical alterations in rats. J Neurosci Res 80:442-449.
34. Young JM, Shytle RD, Sanberg PR, and George TP (2001) Mecamylamine: new therapeutic uses and toxicity/risk profile. Clin Ther 23:532-565.
35. Zhao L, Kuo YP, George AA, Peng JH, Purandare MS, Schroeder KM, Lukas RJ, and Wu J (2003) Functional properties of homomeric, human α7-nicotinic acetylcholine receptors heterologously expressed in the SH-EP1 human epithelial cell line. J Pharmacol Exp Ther 305:1132-1141.
36. Zhao X, Salgado VL, Yeh JZ, and Narahashi T (2004) Kinetic and pharmacological characterization of desensitizing and non-desensitizing glutamate-gated chloride channels in cockroach neurons. Neurotoxicology 25:967-980.